INTerpath-004: A phase 2, randomized, doubleblind study of pembrolizumab with V940 (mRNA- 4157) or placebo in the adjuvant treatment of renal cell carcinoma
No Thumbnail Available
Authors
Choueiri,T. K.
Powles,T.
Braun,D.
Fong,L.
George,D.
Haas,N.
McDermott,D. F.
Shuch,B.
Gurney,H.
Meehan,R.
Contact
Check for full-text access
Issue Date
2024
Type
Conference Proceedings
Language
Keywords
Alternative Title
Abstract
Background: The PD-1 inhibitor pembrolizumab is approved as monotherapy for the adjuvant treatment of patients with renal cell carcinoma (RCC) who are at increased risk of recurrence following nephrectomy or nephrectomy and resection of metastatic lesions based on results from the phase 3 KEYNOTE-564 trial. Novel combination strategies could provide further clinical benefit in the adjuvant setting. V940 (mRNA-4157) is an individualized neoantigen therapy that is hypothesized to increase the antitumor activity of T cells and enhance the activity of pembrolizumab. V940 plus pembrolizumab showed improved clinical outcomes for stage III/IV melanoma compared with pembrolizumab alone in the phase 2b KEYNOTE-942 study. INTerpath-004 is a global, multicenter, randomized, doubleblind, phase 2 trial (NCT06307431) designed to evaluate the efficacy and safety of adjuvant pembrolizumab with V940 or placebo in patients with RCC who have undergone nephrectomy.
Description
Citation
Publisher
License
Journal
The Oncologist